{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:54:45Z","timestamp":1791572085254,"version":"4.3.4"},"reference-count":41,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","award":["10.46540\/4308-00130B"],"award-info":[{"award-number":["10.46540\/4308-00130B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>What is the impact of chemotherapy on the ovarian reserve in premenopausal women diagnosed with breast cancer, and how is this impacted by fertility preservation (FP) strategy and age at diagnosis?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>Chemotherapy reduces ovarian reserve in women with breast cancer, with the greatest reductions observed among women who underwent ovarian tissue cryopreservation (OTC) and those of advanced reproductive age (\u226535\u2009years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>Breast cancer is the most prevalent cancer among women of reproductive age, and in recent decades increasing emphasis has been placed on FP, including ovarian tissue, embryo, and oocyte cryopreservation. However, few large prospective studies have evaluated the effect of chemotherapy on ovarian reserve in patients with breast cancer using both anti-M\u00fcllerian hormone (AMH) and antral follicle count (AFC), and no large studies have assessed the impact by choice of FP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>In this combined retro and prospective cohort study, we included 152 premenopausal women diagnosed with breast cancer who received FP counselling at Rigshospitalet, Copenhagen University Hospital, between 1 January 2018 and 31 August 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>Women aged 18\u201342\u2009years scheduled for FP counselling before chemotherapy were included. Exclusion criteria were previous chemotherapy, oophorectomy, and death or emigration within 2\u00a0years of inclusion. Medical and gynecological history, and oncological treatment plans were recorded. Ovarian reserve was assessed using AMH and AFC at baseline and at 6, 12, and 24\u2009months after chemotherapy. Changes over time were analyzed using linear mixed models adjusted for age at baseline and hormonal contraceptive use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>Of 152 women, 57 underwent OTC, while 41 underwent oocyte\/embryo cryopreservation and 54 had no FP. Baseline median AMH was 13.9 [95% CI: 10.7, 18.1] pmol\/l among women who did not undergo OTC and 13.3 [10.9, 16.3] pmol\/l among those who did. A marked reduction in both AMH and AFC was observed after chemotherapy, with partial recovery within 2\u00a0years after treatment. The reduction was more pronounced, and recovery more limited, in women with OTC and in those of advanced reproductive age (\u226535\u2009years). Compared to baseline, the adjusted reduction in median AMH was 90% [95% CI: 85%, 93%] at 6\u2009months and 75% [95% CI: 63%, 83%] at 24\u2009months in women without OTC and 93% [95% CI: 85%, 95%] and 85% [95% CI: 78%, 90%] in women with OTC, respectively. Similar patterns, however, not as profound, were seen for AFC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>Not all women completed assessments at all three follow-up visits, likely reflecting emotional exhaustion, hospital fatigue, reluctance to attend additional appointments, or changes in reproductive intentions. Furthermore, the observed reduction in ovarian reserve may, to some extent, also reflect the natural age-related decline in ovarian reserve.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>These findings may support counselling women with breast cancer about chemotherapy-related ovarian damage and thus the need for FP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>FUNDING<\/jats:title>\n                    <jats:p>The study is funded by the Independent Research Fund Denmark (Grant ID 10.46540\/4308-00130B).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCLOSURES<\/jats:title>\n                    <jats:p>A.P. has received grants (paid to the institution) and consulting fees from Gedeon Richter, Ferring Pharmaceuticals, Merck A\/S, and Cryos; honoraria from Gedeon Richter, Ferring Pharmaceuticals, Merck A\/S, and Organon; and support for meeting attendance and\/or travel (paid to the institution) from Gedeon Richter. A.T.P. received speaker fees from Astellas, Gedeon-Richter, and Novo Nordisk. These companies had no role in the study. The other authors have no conflicts or interests to declare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>N\/A.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/deag156","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:25:52Z","timestamp":1789673152000},"source":"Crossref","is-referenced-by-count":0,"title":["Ovarian reserve after chemotherapy in premenopausal women with breast cancer undergoing fertility preservation counselling with and without unilateral ovarian tissue cryopreservation"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7249-5442","authenticated-orcid":false,"given":"Anna Mathilde","family":"Yde","sequence":"first","affiliation":[{"name":"The Fertility Clinic, Department of Gynecology, Fertility and Obstetrics, Copenhagen University Hospital, Rigshospitalet , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7570-2822","authenticated-orcid":false,"given":"Lotte Berdiin","family":"Colmorn","sequence":"additional","affiliation":[{"name":"The Fertility Clinic, Department of Gynecology, Fertility and Obstetrics, Copenhagen University Hospital, Rigshospitalet , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8340-104X","authenticated-orcid":false,"given":"Anja","family":"Pinborg","sequence":"additional","affiliation":[{"name":"The Fertility Clinic, Department of Gynecology, Fertility and Obstetrics, Copenhagen University Hospital, Rigshospitalet , Copenhagen,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-0869","authenticated-orcid":false,"given":"Julie Lyng","family":"Forman","sequence":"additional","affiliation":[{"name":"Section of Biostatistics, Department of Public Health, University of Copenhagen , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida-Marie H\u00f8jgaard","family":"Prietzel","sequence":"additional","affiliation":[{"name":"The Fertility Clinic, Department of Gynecology, Fertility and Obstetrics, Copenhagen University Hospital, Rigshospitalet , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharyn","family":"Stern","sequence":"additional","affiliation":[{"name":"Reproductive Services Unit, Royal Women\u2019s Hospital , Parkville, Victoria,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1194-8393","authenticated-orcid":false,"given":"Stine Gry","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Laboratory of Reproductive Biology, Department of Gynaecology, Fertility and Obstetrics, Copenhagen University Hospital, Rigshospitalet , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene Hee","family":"Christensen","sequence":"additional","affiliation":[{"name":"The Fertility Clinic, Department of Gynecology, Fertility and Obstetrics, Copenhagen University Hospital, Rigshospitalet , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Clare","family":"Larsen","sequence":"additional","affiliation":[{"name":"The Fertility Clinic, Department of Gynecology, Fertility and Obstetrics, Copenhagen University Hospital, Rigshospitalet , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette T\u00f8nnes","family":"Pedersen","sequence":"additional","affiliation":[{"name":"The Fertility Clinic, Department of Gynecology, Fertility and Obstetrics, Copenhagen University Hospital, Rigshospitalet , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten Tryde","family":"Macklon","sequence":"additional","affiliation":[{"name":"The Fertility Clinic, Department of Gynecology, Fertility and Obstetrics, Copenhagen University Hospital, Rigshospitalet , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"2026100914304125100_deag156-B1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/humrep\/dey098","article-title":"Discordance between serum anti-M\u00fcllerian hormone concentrations and antral follicle counts: not only technical issues","volume":"33","author":"Alebi\u0107","year":"2018","journal-title":"Hum Reprod"},{"key":"2026100914304125100_deag156-B2","doi-asserted-by":"crossref","first-page":"hoaa052","DOI":"10.1093\/hropen\/hoaa052","article-title":"ESHRE guideline: female fertility preservation\u2020","volume":"2020","author":"Anderson","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2026100914304125100_deag156-B3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/humrep\/dey216","article-title":"The impact of cancer on subsequent chance of pregnancy: a population-based analysis","volume":"33","author":"Anderson","year":"2018","journal-title":"Hum Reprod"},{"key":"2026100914304125100_deag156-B4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/humupd\/dmac004","article-title":"Anti-M\u00fcllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review","volume":"28","author":"Anderson","year":"2022","journal-title":"Hum Reprod Update"},{"key":"2026100914304125100_deag156-B5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-021-06508-w","article-title":"Diagnostic and predictive accuracy of anti-Mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer","volume":"192","author":"Anderson","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2026100914304125100_deag156-B6","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1016\/j.ejca.2013.07.014","article-title":"Pretreatment anti-M\u00fcllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer","volume":"49","author":"Anderson","year":"2013","journal-title":"Eur J Cancer"},{"key":"2026100914304125100_deag156-B7","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/humrep\/del201","article-title":"The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer","volume":"21","author":"Anderson","year":"2006","journal-title":"Hum Reprod"},{"key":"2026100914304125100_deag156-B8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.rbmo.2017.10.109","article-title":"Fertility protection: complications of surgery and results of removal and transplantation of ovarian tissue","volume":"36","author":"Beckmann","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"2026100914304125100_deag156-B9","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2217\/fon-2016-0176","article-title":"Chemotherapy-induced damage to ovary: mechanisms and clinical impact","volume":"12","author":"Bedoschi","year":"2016","journal-title":"Future Oncol"},{"key":"2026100914304125100_deag156-B10","first-page":"421","article-title":"Thoughts about fertility among female adolescents and young adults with cancer: a qualitative study","volume":"31","author":"Bentsen","year":"2023","journal-title":"Support Care Cancer"},{"key":"2026100914304125100_deag156-B11","doi-asserted-by":"crossref","first-page":"102035","DOI":"10.1016\/j.jogoh.2020.102035","article-title":"Evaluation of ovarian reserve before and after chemotherapy","volume":"50","author":"Berjeb","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2026100914304125100_deag156-B12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.fertnstert.2009.04.040","article-title":"The antral follicle count: practical recommendations for better standardization","volume":"94","author":"Broekmans","year":"2010","journal-title":"Fertil Steril"},{"key":"2026100914304125100_deag156-B13","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1210\/jc.2010-2776","article-title":"Anti-M\u00fcllerian hormone predicts menopause: a long-term follow-up study in normoovulatory women","volume":"96","author":"Broer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100914304125100_deag156-B14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.fertnstert.2007.12.013","article-title":"The role of antiMullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count","volume":"91","author":"Broer","year":"2009","journal-title":"Fertil Steril"},{"key":"2026100914304125100_deag156-B15","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1210\/jc.2018-02257","article-title":"Differential rates of change in measures of ovarian reserve in young cancer survivors across the reproductive lifespan","volume":"104","author":"Cameron","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100914304125100_deag156-B16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-0037-1601438","article-title":"Antral follicles count and anti-M\u00fcllerian hormone levels after gonadotoxic chemotherapy in patients with breast cancer: cohort study","volume":"39","author":"D\u2019Avila","year":"2017","journal-title":"Rev Bras Ginecol Obstet"},{"key":"2026100914304125100_deag156-B17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2017.03.035","article-title":"Prospective evaluation of serum anti-M\u00fcllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer","volume":"79","author":"Dezellus","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026100914304125100_deag156-B18","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMra1614676","article-title":"Fertility preservation in women","volume":"377","author":"Donnez","year":"2017","journal-title":"N Engl J Med"},{"key":"2026100914304125100_deag156-B19","author":"Fertility Statistics \u2013 Statistics Explained"},{"key":"2026100914304125100_deag156-B20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.rbmo.2014.07.008","article-title":"Ovarian reserve in breast cancer: assessment with anti-M\u00fcllerian hormone","volume":"29","author":"Hamy","year":"2014","journal-title":"Reprod Biomed Online"},{"key":"2026100914304125100_deag156-B21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/molehr\/gat024","article-title":"Which follicles make the most anti-M\u00fcllerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection","volume":"19","author":"Jeppesen","year":"2013","journal-title":"Mol Hum Reprod"},{"key":"2026100914304125100_deag156-B22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cyto.a.24297","article-title":"After cyclophosphamide exposure, granulosa cells recover their anti-M\u00fcllerian hormone-producing ability but not their numbers","volume":"99","author":"Kim","year":"2021","journal-title":"Cytometry A"},{"key":"2026100914304125100_deag156-B23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1477-7827-11-60","article-title":"Anti-Mullerian-hormone levels during pregnancy and postpartum","volume":"11","author":"K\u00f6ninger","year":"2013","journal-title":"Reprod Biol Endocrinol"},{"key":"2026100914304125100_deag156-B24","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/jnci\/djaf198","article-title":"Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients","volume":"117","author":"Lambertini","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"2026100914304125100_deag156-B25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.rbmo.2019.05.016","article-title":"The female post-cancer fertility-counselling clinic: looking beyond the freezer. A much needed addition to oncofertility care","volume":"39","author":"Macklon","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"2026100914304125100_deag156-B26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0303-7207(00)00365-8","article-title":"Reproduction post-chemotherapy in young cancer patients","volume":"169","author":"Meirow","year":"2000","journal-title":"Mol Cell Endocrinol"},{"key":"2026100914304125100_deag156-B27","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/humrep\/dem027","article-title":"Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury","volume":"22","author":"Meirow","year":"2007","journal-title":"Hum Reprod"},{"key":"2026100914304125100_deag156-B28","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.fertnstert.2009.07.1676","article-title":"Longitudinal assessment of antiM\u00fcllerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin","volume":"93","author":"Nelson","year":"2010","journal-title":"Fertil Steril"},{"key":"2026100914304125100_deag156-B29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/humrep\/den480","article-title":"Anti-M\u00fcllerian hormone-based approach to controlled ovarian stimulation for assisted conception","volume":"24","author":"Nelson","year":"2009","journal-title":"Hum Reprod"},{"key":"2026100914304125100_deag156-B30","volume-title":"Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 9.5.","author":"NORDCAN 2.0"},{"key":"2026100914304125100_deag156-B31","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.fertnstert.2020.09.134","article-title":"Testing and interpreting measures of ovarian reserve: a committee opinion","volume":"114","author":"Penzias","year":"2020","journal-title":"Fertil Steril"},{"key":"2026100914304125100_deag156-B32","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.rbmo.2017.06.005","article-title":"Influence of adjuvant chemotherapy on anti-M\u00fcllerian hormone in women below 35 years treated for early breast cancer","volume":"35","author":"Perdrix","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2026100914304125100_deag156-B33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.rbmo.2010.10.015","article-title":"Cryopreservation of ovarian tissue for a decade in Denmark: a view of the technique","volume":"22","author":"Rosendahl","year":"2011","journal-title":"Reprod Biomed Online"},{"key":"2026100914304125100_deag156-B34","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s10815-018-1203-8","article-title":"Antral follicle count recovery in women with menses after treatment with and without gonadotropin-releasing hormone agonist use during chemotherapy for breast cancer","volume":"35","author":"Sinha","year":"2018","journal-title":"J Assist Reprod Genet"},{"key":"2026100914304125100_deag156-B35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dmz027","article-title":"Ovarian damage from chemotherapy and current approaches to its protection","volume":"25","author":"Spears","year":"2019","journal-title":"Hum Reprod Update"},{"key":"2026100914304125100_deag156-B36","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1210\/clinem\/dgaa172","article-title":"Modeling variation in the reproductive lifespan of female adolescent and young adult cancer survivors using AMH","volume":"105","author":"Su","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100914304125100_deag156-B37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.breast.2017.07.007","article-title":"Anti-M\u00fcllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy \u2013 a translational research project of the SUCCESS A study","volume":"35","author":"Trapp","year":"2017","journal-title":"Breast"},{"key":"2026100914304125100_deag156-B38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/molehr\/gah015","article-title":"Anti-M\u00fcllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment","volume":"10","author":"Weenen","year":"2004","journal-title":"Mol Hum Reprod"},{"key":"2026100914304125100_deag156-B39","doi-asserted-by":"crossref","first-page":"hoaf068","DOI":"10.1093\/hropen\/hoaf068","article-title":"Return rates for the use of ovarian tissue cryopreserved prior to gonadotoxic treatment as fertility preservation: a systematic review","volume":"2025","author":"Yde","year":"2025","journal-title":"Hum Reprod Open"},{"key":"2026100914304125100_deag156-B40","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1093\/humrep\/deaf192","article-title":"Livebirth among 5940 Danish women diagnosed with breast cancer at age 18\u201340 years between 1968 and 2016: a register-based cohort study","volume":"40","author":"Yde","year":"2025","journal-title":"Hum Reprod"},{"key":"2026100914304125100_deag156-B41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.fertnstert.2024.11.007","article-title":"Evidence-based guideline: premature ovarian insufficiency","volume":"123","author":"Yeganeh","year":"2025","journal-title":"Fertil Steril"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/advance-article-pdf\/doi\/10.1093\/humrep\/deag156\/71789686\/deag156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/advance-article-pdf\/doi\/10.1093\/humrep\/deag156\/71789686\/deag156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:30:54Z","timestamp":1791570654000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/advance-article\/doi\/10.1093\/humrep\/deag156\/8898806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1093\/humrep\/deag156","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"deag156"}}